Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease

Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease

In Huntington's disease (HD) mutant huntingtin protein impairs the function of several transcription factors, in particular the cAMP response element-binding protein (CREB). CREB activation can be increased by targeting phosphodiesterases such as phospohodiesterase 4 (PDE4) and phosphodiesteras...

Full description

Bibliographic Details
Main Authors:	Alessandro Leuti, Daunia Laurenti, Carmela Giampà, Elena Montagna, Clemente Dato, Serenella Anzilotti, Mariarosa A.B. Melone, Giorgio Bernardi, Francesca R. Fusco
Format:	Article
Language:	English
Published:	Elsevier 2013-04-01
Series:	Neurobiology of Disease
Subjects:	Huntington's disease PDE10A Striatum Immunohistochemistry
Online Access:	http://www.sciencedirect.com/science/article/pii/S0969996112003798

Similar Items

Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease
by: Carmela Giampà, et al.
Published: (2009-06-01)

Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition
by: Francesca R. Fusco, et al.
Published: (2012-04-01)

Phosphodiesterase 10A (PDE10A): Regulator of Dopamine Agonist-Induced Gene Expression in the Striatum
by: Ryan Bonate, et al.
Published: (2022-07-01)

Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions
by: Marianna Szczypka
Published: (2020-08-01)

Proteostasis in striatal cells and selective neurodegeneration in Huntington’s disease
by: Julia eMargulis, et al.
Published: (2014-08-01)

Phosphodiesterase 1b (PDE1B) Regulates Spatial and Contextual Memory in Hippocampus
by: Susan McQuown, et al.
Published: (2019-02-01)

Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease.
by: Carmela Giampà, et al.
Published: (2013-01-01)

Correction: Systemic Delivery of Recombinant Brain Derived Neurotrophic Factor (BDNF) in the R6/2 Mouse Model of Huntington's Disease.
by: Carmela Giampà, et al.
Published: (2016-01-01)

Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer
by: Rebecca M. Borneman, et al.
Published: (2022-11-01)

BACHD Mice Recapitulate the Striatal Parvalbuminergic Interneuron Loss Found in Huntington’s Disease
by: Vyshnavi Rallapalle, et al.
Published: (2021-05-01)

Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington’s disease
by: Laetitia eFrancelle, et al.
Published: (2014-09-01)

Pathological characterization of T2*-weighted MRI contrast in the striatum of Huntington’s disease patients
by: Marjolein Bulk, et al.
Published: (2020-01-01)

Functional changes in neocortical activity in Huntington's Disease model mice: an in vivo intracellular study.
by: Edward A Stern
Published: (2011-06-01)

The specific role of the striatum in interval timing: The Huntington’s disease model
by: Laurie Lemoine, et al.
Published: (2021-01-01)

PDE4 Phosphodiesterases in Cardiovascular Diseases: Key Pathophysiological Players and Potential Therapeutic Targets
by: Lídia Puertas-Umbert, et al.
Published: (2023-11-01)

Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease
by: Zena DeMarch, et al.
Published: (2008-06-01)

A Promising Biomolecule Able to Degrade Neutrophil Extracellular Traps: <i>Cdc</i>PDE, a Rattlesnake Phosphodiesterase
by: Isadora Oliveira, et al.
Published: (2023-01-01)

Dominant-Negative Attenuation of cAMP-Selective Phosphodiesterase PDE4D Action Affects Learning and Behavior
by: Graeme B. Bolger, et al.
Published: (2020-08-01)

Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats
by: Orsolya Kántor, et al.
Published: (2006-06-01)

Intergenerational and striatal CAG repeat instability in Huntington's disease knock-in mice involve different DNA repair genes
by: Ella Dragileva, et al.
Published: (2009-01-01)

The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches
by: Claire Lugnier
Published: (2022-09-01)

Phospholipid Profiles Are Selectively Altered in the Putamen and White Frontal Cortex of Huntington’s Disease
by: Gabrielle R. Phillips, et al.
Published: (2022-05-01)

Deficits in coordinated neuronal activity and network topology are striatal hallmarks in Huntington’s disease
by: S. Fernández-García, et al.
Published: (2020-05-01)

Reactive Neuroblastosis in Huntington’s Disease: A Putative Therapeutic Target for Striatal Regeneration in the Adult Brain
by: Mahesh Kandasamy, et al.
Published: (2018-03-01)

Evidence for Dysfunction of the Nigrostriatal Pathway in the R6/1 Line of Transgenic Huntington's Disease Mice
by: Å. Petersén, et al.
Published: (2002-10-01)

Resolving pathobiological mechanisms relating to Huntington disease: Gait, balance, and involuntary movements in mice with targeted ablation of striatal D1 dopamine receptor cells
by: Hyun Ah. Kim, et al.
Published: (2014-02-01)

Alterations of striatal indirect pathway neurons precede motor deficits in two mouse models of Huntington's disease
by: Irene Sebastianutto, et al.
Published: (2017-09-01)

Brain Region and Cell Compartment Dependent Regulation of Electron Transport System Components in Huntington’s Disease Model Mice
by: Johannes Burtscher, et al.
Published: (2021-09-01)

Striatal Network Models of Huntington's Disease Dysfunction Phenotypes
by: Pengsheng Zheng, et al.
Published: (2017-07-01)

Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity
by: Ryoma Morigaki, et al.
Published: (2017-06-01)

Minocycline in phenotypic models of Huntington's disease
by: Kadiombo Bantubungi, et al.
Published: (2005-02-01)

Emerging Potential of the Phosphodiesterase (PDE) Inhibitor Ibudilast for Neurodegenerative Diseases: An Update on Preclinical and Clinical Evidence
by: Efthalia Angelopoulou, et al.
Published: (2022-12-01)

Genetic Association of Phosphodiesterases With Human Cognitive Performance
by: Mark E. Gurney
Published: (2019-02-01)

Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8)
by: Chaitali P. Basole, et al.
Published: (2022-02-01)

Dysregulation of coordinated neuronal firing patterns in striatum of freely behaving transgenic rats that model Huntington's disease
by: Benjamin R. Miller, et al.
Published: (2010-01-01)

CAG repeat lengths ≥335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse
by: I. Dragatsis, et al.
Published: (2009-03-01)

Preserving cortico-striatal function: Deep brain stimulation in Huntington's disease
by: Sean J Nagel, et al.
Published: (2015-03-01)

Modulation of Inflammasome and Pyroptosis by Olaparib, a PARP-1 Inhibitor, in the R6/2 Mouse Model of Huntington’s Disease
by: Emanuela Paldino, et al.
Published: (2020-10-01)

Selective Inhibition of Phosphodiesterase 7 (PDE7) by BRL50481 in Healthy and Ovalbumin-Sensitized Guinea Pigs
by: Christensen I., et al.
Published: (2012-02-01)

Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review
by: Andrew Blauvelt, et al.
Published: (2023-11-01)